O	0	1	A
O	2	13	prospective
O	14	24	randomized
O	24	25	,
O	26	33	placebo
O	33	34	-
O	34	44	controlled
O	45	49	skin
O	50	54	care
O	55	60	study
O	61	63	in
O	64	69	women
O	70	79	diagnosed
O	80	84	with
O	85	91	breast
O	92	98	cancer
O	99	109	undergoing
O	110	119	radiation
O	120	127	therapy
O	127	128	.

O	129	131	To
O	132	139	compare
O	140	143	the
O	144	157	effectiveness
O	158	160	of
O	161	166	three
O	167	176	different
B-intervention	177	181	skin
I-intervention	182	186	care
I-intervention	187	195	products
O	196	202	versus
O	203	204	a
B-control	205	212	placebo
O	213	215	in
O	216	224	reducing
O	225	228	the
O	229	238	incidence
O	239	241	of
B-condition	242	251	radiation
I-condition	252	259	therapy
I-condition	259	260	-
I-condition	260	267	induced
I-condition	268	272	skin
I-condition	273	282	reactions
O	283	299	prophylactically
O	299	300	.

O	301	312	Prospective
O	313	323	randomized
O	323	324	,
O	325	331	double
O	331	332	-
O	332	339	blinded
O	339	340	,
O	341	348	placebo
O	348	349	-
O	349	359	controlled
O	360	365	study
O	365	366	.

O	367	368	A
O	369	378	radiation
O	379	387	oncology
O	388	398	department
O	399	401	at
O	402	403	a
O	404	412	National
O	413	419	Cancer
O	420	429	Institute
O	429	430	-
O	430	440	designated
O	441	454	comprehensive
O	455	461	cancer
O	462	468	center
O	469	471	in
O	472	475	the
B-location	476	488	southeastern
I-location	489	495	United
I-location	496	502	States
O	502	503	.

B-total-participants	504	507	208
B-eligibility	508	513	women
I-eligibility	514	518	with
I-eligibility	519	525	breast
I-eligibility	526	532	cancer
I-eligibility	533	536	who
I-eligibility	537	541	were
I-eligibility	542	544	to
I-eligibility	545	552	receive
I-eligibility	553	558	whole
I-eligibility	559	565	breast
I-eligibility	566	575	radiation
I-eligibility	576	583	therapy
O	583	584	.

O	585	593	Patients
O	594	598	were
O	599	606	invited
O	607	609	to
O	610	621	participate
O	622	627	after
O	628	637	radiation
O	638	645	therapy
O	646	649	was
O	650	660	documented
O	661	663	as
O	664	668	part
O	669	671	of
O	672	677	their
O	678	687	treatment
O	688	692	plan
O	692	693	.

O	694	702	Patients
O	703	710	applied
O	711	712	a
O	713	717	skin
O	718	722	care
O	723	730	product
O	731	739	starting
O	740	742	on
O	743	746	the
O	747	752	first
O	753	756	day
O	757	759	of
O	760	769	treatment
O	770	773	and
O	774	778	were
O	779	787	assessed
O	788	794	weekly
O	795	797	by
O	798	803	their
O	804	813	radiation
O	814	822	oncology
O	823	828	nurse
O	828	829	.

O	830	834	Skin
O	835	843	reaction
O	844	849	score
O	850	853	and
O	854	858	skin
O	859	866	product
O	866	867	.

O	868	872	None
O	873	875	of
O	876	879	the
O	880	888	products
O	889	893	were
O	894	907	statistically
O	908	914	better
O	915	919	than
O	920	927	placebo
O	928	930	in
B-outcome	931	941	preventing
I-outcome	942	946	skin
I-outcome	947	956	reactions
O	956	957	.

B-outcome	958	967	Increases
I-outcome	968	970	in
I-outcome	971	975	skin
I-outcome	976	984	reaction
O	985	989	over
O	990	994	time
O	995	998	did
O	999	1002	not
O	1003	1007	vary
O	1008	1012	with
O	1013	1022	treatment
O	1023	1028	group
O	1029	1032	for
O	1033	1036	the
O	1037	1043	linear
O	1044	1045	(
O	1045	1046	p
O	1047	1048	=
O	1049	1050	0
O	1050	1051	.
O	1051	1053	16
O	1053	1054	)
O	1055	1058	and
O	1059	1068	nonlinear
O	1069	1070	(
O	1070	1071	p
O	1072	1073	=
O	1074	1075	0
O	1075	1076	.
O	1076	1078	94
O	1078	1079	)
O	1080	1087	effects
O	1088	1090	of
O	1091	1095	time
O	1096	1099	and
O	1100	1103	for
O	1104	1108	both
O	1109	1113	time
O	1114	1124	components
O	1125	1131	tested
O	1132	1140	together
O	1141	1142	(
O	1142	1143	p
O	1144	1145	=
O	1146	1147	0
O	1147	1148	.
O	1148	1150	41
O	1150	1151	)
O	1151	1152	.

O	1153	1159	Ninety
O	1159	1160	-
O	1160	1164	five
O	1165	1172	percent
O	1173	1175	of
O	1176	1181	women
O	1182	1195	participating
O	1196	1198	in
O	1199	1203	this
O	1204	1209	study
O	1210	1221	experienced
O	1222	1223	a
B-outcome	1224	1233	radiation
I-outcome	1234	1241	therapy
I-outcome	1241	1242	-
I-outcome	1242	1249	induced
I-outcome	1250	1254	skin
I-outcome	1255	1263	reaction
O	1263	1264	.

O	1265	1268	The
O	1269	1280	development
O	1281	1283	of
O	1284	1294	guidelines
O	1295	1297	to
O	1298	1305	support
O	1306	1310	safe
O	1311	1318	patient
O	1319	1323	care
O	1324	1326	is
O	1327	1337	encouraged
O	1338	1345	because
O	1346	1354	patients
O	1355	1361	prefer
O	1362	1364	to
O	1365	1369	take
O	1370	1376	action
O	1377	1383	rather
O	1384	1388	than
O	1389	1391	do
O	1392	1399	nothing
O	1399	1400	.

O	1401	1408	However
O	1408	1409	,
O	1410	1413	the
O	1414	1422	findings
O	1423	1425	do
O	1426	1429	not
O	1430	1441	demonstrate
O	1442	1450	improved
O	1451	1459	clinical
O	1460	1468	outcomes
O	1469	1473	with
O	1474	1477	the
O	1478	1481	use
O	1482	1484	of
O	1485	1489	skin
O	1490	1494	care
O	1495	1503	products
O	1503	1504	.

O	1505	1515	Healthcare
O	1516	1525	providers
O	1526	1532	should
O	1533	1544	proactively
O	1545	1552	educate
O	1553	1561	patients
O	1562	1567	about
O	1568	1573	acute
O	1574	1578	skin
O	1579	1588	reactions
O	1589	1592	and
O	1593	1597	self
O	1597	1598	-
O	1598	1602	care
O	1603	1613	strategies
O	1614	1616	to
O	1617	1625	minimize
O	1626	1630	skin
O	1631	1640	breakdown
O	1640	1641	.
